CymaBay Therapeutics shares jumped nearly 25% and hit a new record high in early trading after the clinical-stage biopharmaceutical company agreed to be acquired by Gilead Sciences for $4.3 billion.
Trending
- Asteroid 2026 JH2 — no need to worry about it hitting Earth
- New Ebola outbreak 'kills 80' in Democratic Republic of Congo
- X pledges quicker action on hate and terror content in the UK
- Hantavirus close contacts in France have so far tested negative
- Mbappé heads up France squad in Deschamps' final World Cup bid
- World Cup market in India and China: ‘FIFA got greedy’
- Is home ownership still part of the American Dream?
- Oil price gains and Westminster worry sink stocks
